Dynamics of Circulating y   T Cell Activity in an Immunocompetent @entity19 Model of XXXX .

@entity1 @entity19 @entity7097 @entity5 @entity12810 @entity11 @entity58 @entity10440 @entity636 @entity3132 @entity463
UNASSIGNED: @entity1 y   T cells are potent effectors against @entity11 cell lines in vitro and in @entity1 / @entity19 xenograft models of @entity463 , however, this effect has not been investigated in an immunocompetent @entity19 model. In this report, we established GL261 @entity11 in @entity7097 /6 @entity19 and measured circulating y   T cell count, phenotype, Vy/V   repertoire, @entity5 histopathology, @entity3132 ligands expression, and T cell invasion at day 10-12 post-injection and at end stage. Circulating y   T cells transiently increased and upregulated @entity10440 expression at post- @entity5 day 10-12 followed by a dramatic decline in y   T cell count at end stage. T cell receptor repertoire showed no changes in Vy1, Vy4, Vy7 or V  1 subsets from controls at post- @entity5 day 10-12 or at end stage except for an end-stage increase in the V  4 population. Approximately 12% of y   T cells produced IFN-y. @entity636 and @entity58 producing y   T cells were not detected. @entity5 progression was the same in @entity12810  -/- C57BL/6 @entity19 as that observed in WT @entity19 , suggesting that y   T cells exerted neither a regulatory nor a sustainable cytotoxic effect on the @entity5 . WT @entity19 that received an intracranial injection of y   T cells 15m following @entity5 placement showed evidence of @entity5 growth inhibition but this was insufficient to confer a survival advantage over untreated controls. Taken together, our findings suggest that an early nonspecific proliferation of y   T cells followed by their depletion occurs in @entity19 implanted with @entity11 . The mechanism by which y   T cell expansion occurs remains a subject for further investigation of the mechanisms responsible for this immune response in the setting of high-grade @entity11 .
